Go Deep
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -116,928 | 40.6 | 209.99 | 23.86 | 1,923.08 |
| Oct 2026 | -118,110 | 40.9 | 211.25 | 23.86 | 1,917.68 |
| Oct 2026 | -103,642 | 39.9 | 206.40 | 23.86 | 1,863.72 |
| Oct 2026 | -99,949 | 38.6 | 199.33 | 23.86 | 1,794.51 |
| Oct 2026 | -101,880 | 41.0 | 203.03 | 23.86 | 1,828.00 |
| Oct 2026 | -101,493 | 39.1 | 202.29 | 23.86 | 1,816.63 |
| Oct 2026 | -102,485 | 39.5 | 204.19 | 23.86 | 1,835.65 |
| Oct 2026 | -105,130 | 40.5 | 209.25 | 23.86 | 1,881.16 |
| Oct 2026 | -107,115 | 41.2 | 213.04 | 23.86 | 1,910.56 |
| Oct 2026 | -108,658 | 41.8 | 216.00 | 23.86 | 1,933.12 |
Amneal Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 796,197,000.0 | 722,519,000.0 | 814,319,000.0 | 784,513,000.0 |
| Net Profit | 57,662,000.0 | 62,256,000.0 | 35,076,000.0 | 2,369,000.0 |
| EPS | 0.2 | 0.2 | 0.1 | 0.0 |
Amneal Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 3,018,760,000.0 | 2,793,957,000.0 | 2,393,607,000.0 | 2,212,304,000.0 | — |
| Net Profit | 72,057,000.0 | -116,886,000.0 | -83,993,000.0 | -129,986,000.0 | — |
| EPS | 0.2 | -0.4 | -0.5 | -0.9 | — |
Amneal Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 3,678,280,000.0 | 3,501,445,000.0 | 3,472,569,000.0 | 3,799,341,000.0 | — |
| Total Liabilities | 3,749,609,000.0 | 3,610,957,000.0 | 3,452,558,000.0 | 3,615,362,000.0 | — |
| Total Equity | -70,794,000.0 | -109,267,000.0 | 19,781,000.0 | 298,421,000.0 | — |
Owes vs Owns
Amneal Pharmaceuticals, Inc. owed $0.99 for every $1 it owned in Jun 2026, up from $0.95 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.99× | 1.02× | 1.03× | 0.99× | 0.95× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Amneal Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 7.7%Receivables 25.6%Inventory 16.5%Fixed assets (tangible) 15.0%Intangible assets 31.5%Other assets 3.8%
How it's funded — Dec 2025
Long-term debt 68.4%Payables 6.8%Other liabilities 24.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 282.0 | 110.6 | 91.5 | 26.0 |
| Receivables | 939.9 | 808.6 | 645.7 | 796.9 |
| Inventory | 606.3 | 612.5 | 581.4 | 530.7 |
| Fixed assets (tangible) | 550.3 | 523.7 | 550.1 | 589.4 |
| Intangible assets | 1,159.0 | 1,329.8 | 1,489.1 | 1,694.9 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 140.8 | 116.4 | 114.8 | 161.4 |
| Liabilities & equity | ||||
| Short-term debt | 6.8 | 324.2 | 213.1 | 90.0 |
| Long-term debt | 2,565.1 | 2,161.8 | 2,427.5 | 2,631.7 |
| Payables | 254.7 | 258.7 | 143.6 | 166.0 |
| Other liabilities | 923.1 | 866.3 | 668.4 | 727.7 |
| Shareholders' equity | -71.3 | -109.5 | 20.0 | 184.0 |
| Net tangible assets | -1,229.8 | -1,439.1 | -1,469.3 | -1,396.5 |
Amneal Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 339,992,000.0 | 295,099,000.0 | 345,577,000.0 | 65,100,000.0 | — |
| Investing Activities | -112,263,000.0 | -62,996,000.0 | -69,189,000.0 | -174,309,000.0 | — |
| Financing Activities | -31,530,000.0 | -211,791,000.0 | -212,573,000.0 | -106,620,000.0 | — |